OPCH — Option Care Health, Inc.

Summary of Option Care Health Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $1.4 billion, up 1% year-over-year, but below expectations.
• Adjusted EBITDA: $105 million, down 6% from the prior year, in line with expectations.
• Adjusted EPS: $0.40, flat compared to the previous year, with a $0.02 uplift from share repurchases.
• Gross Profit: Slight decline due to lower chronic therapy revenue; a revised estimate for gross profit headwind from the Chronic Inflammatory Disease (CID) portfolio is now $55 million, up from a prior estimate of $25-$35 million.
• Operating Cash Flow: A usage of $12 million, consistent with seasonal expectations.
• Net Debt to Leverage Ratio: 2.2x, with an expanded revolving credit facility from $400 million to $850 million.

2. Strategic Updates and Business Highlights

• Acute Therapy Growth: High single-digit growth driven by strong execution and partnerships with hospitals and health systems.
• Chronic Therapy Challenges: A slight decline in revenue attributed to unexpected patient census resets and therapy mix issues, particularly affecting the CID portfolio.
• Patient Satisfaction: Consistently high patient satisfaction scores in the low 90s and Net Promoter Scores in the mid-70s.
• Ambulatory Infusion Clinics: Increased utilization with a 14% year-over-year growth in visits, now operating in 28 locations.
• Commercial Strategy: Plans to enhance commercial capabilities, including increasing the size of the commercial team and refining the go-to-market model.

3. Forward Guidance and Outlook

• Revenue Guidance: Adjusted to a range of $5.675 billion to $5.775 billion for the full year, reflecting a negative 600 basis point headwind primarily due to CID portfolio issues.
• EBITDA Guidance: Maintained at $480 million to $505 million, with a projected growth of 5% to 9%.
• Operating Cash Flow Target: Adjusted to at least $320 million, considering lower revenue expectations.
• Second Quarter Expectations: Anticipated mid-single-digit revenue growth and high single-digit EBITDA growth sequentially from Q1.

4. Bad News, Challenges, or Points of Concern

• Revenue Growth: Overall revenue growth of only 1% did not meet expectations, with chronic therapy revenue declining and acute therapy growth being the only bright spot.
• CID Portfolio Issues: Significant headwinds from the CID portfolio, particularly related to patient retention and unfavorable therapy mix, leading to a revised outlook.
• Competitive Pressures: Increased competition in the market, with some patients lost to competitors due to changes in health plans and formulary management.
• Administrative Delays: Increased patient benefit reverification and authorization processes led to elongated approval timelines, impacting patient transitions and retention.

5. Notable Q&A Insights

• Patient Loss: Management acknowledged losing patients to competitors, particularly due to the transition of Stelara patients to alternative therapies.
• Visibility and Confidence: There is confidence that the reset in patient census is a one-time event, and the company expects to rebuild its patient base moving forward.
• Cost Management: Discussions highlighted ongoing efforts to manage costs, including potential reductions in variable compensation and a focus on maximizing gross profit from acute therapies.
• Long-term Growth Outlook: Despite current challenges, management expressed confidence in returning to a growth trajectory, emphasizing the importance of execution and strategic investments.

Overall, while Option Care Health faces significant challenges in its chronic therapy portfolio and competitive landscape, it maintains a focus on strategic growth initiatives and operational excellence to navigate these headwinds.